What are your thoughts on Cabela's IPO
Cabela's
Collapse
X
-
Carlandjo, Cabela's has a very good reputation according to all I've talked to familiar with the company. Their location nearest to me is in Michigan . It is common for sportsmen to drive over 100 miles to visit Cabela's. Customers seem to view it as a combination amusement park/ retail store. They have 9 stores in several states. Last year income was 51 million. They are attempting to raise 230 million to open new stores. At that figure, 10 million shares issued would be approximately 23.00 per share. This looks real interesting to me. Thanks for bringing this IPO to my attention.
billyjoe
-
-
Their main competition would be the likes of Bass Pro Shops, which is a great place. The only thing is the nearest one to me is 7 hours away. What does that tell me? It tells me there is PLENTY of places for Cabella's to expand to with very little competition. Here in Tallahassee, our best outdoor-type shop is a local place that is so totally overpriced that I will never set foot in there for anything other than rod repair or a reel part. I am going to keep an eye on this one also, thanks!
-Dave
Comment
-
-
Cabela's
Where can you find out an IPO date for a company? I too am a big fan of this store and its concept. One of their competitors here in MN is Gander Mountain. Very similar product line and pricing. GNDR is coming out with an IPO soon to help fuel expansion. Just an FYI for you potential Cabela's investors.
Gander Mountain also opened a big box in the southern metro area of the Twin Cities. That has eliminated the 30-60 minute drive to Cabela's for a lot of us.
Comment
-
-
FYI
This is not concrete Info. A friend of a friend said the call letters will be CAB and an entry price will be around $18.00 per share. This is close to BillyJoe info. Also the f of a f said that she plans on seeing this stock reaching $30.00 to $35.00 in a real short time. If she lets out any more info on this topic I shall pass it along. ===> MEAGO BIG RED!!!!!
Comment
-
-
FWIW
Todays brake time at work was spent reading an artical in a Smart Money Mag, May 04 about IPOs. Atrical title was Fewer Is Better by Nicole Bullock. There where a few statements or one liners I would like to share at this time.
#1 The trend is not your friend.
#2 Of the nearly 900 comp. that went public in the last "BOOM" only 15% are still trading above there IPO. the majority have simply disappeared.
#3 If everybody jumped off a bridge, would you jump TOO?
#4 The worst time is when the bulls are charging.
#5 And history will keep repeating itself.
#6 In bad times, only the most solid comp. rise above the gloom.
#7 Tougher the market === more of a chance the invester will be profitable.
So my ? to all, are we in a tough market or shall we think of ourselves in a mini-boom and this IPO will lead us down the path of GLOOM?
FWIW Just thought I would share these with you, who knows maybe it will help make up your minds on, in or out, how many and at what price. ===> MEAGO BIG RED!!!!!
Comment
-
-
Up Date
The day is here and tommarow is the day. We will just have to wait and see if CAB turns to us for there support or if big monies wil steal the show. It sure would be nice to be able to get in around $16.00 and travel upward to around $26.00 in the years ahead. ===> MEAGO BIG RED!!!!!
Comment
-
-
if you want to gamble.. that what IPO's are ... BUY ELN instead ..next week - or 2 weeks they will here if the FDA will let them fast track Antegren.. this drug ..will be the blockbuster of the next 3 years..
they have built 3 plants to supply the drug.. read about it here
good luck on Cabela ..sporting goods stocks always tricky
READ THIS FROM THE ELAN MEETING LAST WEEK
Thank you, my name is Peter Kinney, I have a question relating to the looking forward and the R & D. A very tantalizing conference call for this year was mentioned that as good as the interim pipeline was, the longer range view was just as exciting or more exciting. And in view also of recent comments by Jim Mullen at Biogen-Idec, twice mentioned in the last ten days, references to possible uses of Antegren in the oncology field. I am wondering if Dr. Ekman or yourself could address that a bit. And then finally, whether there might be another method for delivering of Prialt coming soon.
A: (KM) OK. I'll say a couple of introductory remarks and then Lars, Dr. Ekman would, since we have him here, I would recommend we listen to his comments. I'll start off by saying that Antegren for us is clearly a very significant breakthrough product for us and Biogen as it relates to current therapies, patient need, and what we feel Antegren can do. As great as Antegren is for us we do not, however, become just the Antegren company. So with help from certain members of the board, by Dr. Ekman and his team, we have, over the last decade been working on other things, that over the next several years will come to light, with regard to other things we are doing from a research and a technology point of view, and perhaps Lars, you can spend a few minutes on those. I'll also hit the Prialt question so Lars doesn't have to go into Prialt. We are looking at other ways of administering Prialt with other medical device partners. Lars..
A. (Dr.LE) With regards to other indications and Antegren we are most likely to explore after the MS and Crohn's, the next indication would be RA. We have a huge study, huge Phase II study that is ongoing which will generate results by the first half of the coming year. The next two indications which we have not finally decided with our partner is probably ulcerative colitis. Ulcerative colitis is in many ways similar to Crohn's disease, it hits the colon rather than the small gut. When we will be serving the patients with inflammatory bowel disease, we will meet their physicians, the gastroenterologists, and therefore it's very appealing to serve both patients with Crohn's disease and ulcerative colitis. Further down the line there is experimental evidence that Antegren can play a role in diseases such as Lupus, chronic asthma, and others. Jim Mullen speculated about its role in oncology. There are theoretical arguments for that, but I think that would come way further down the line. We have other things that are more tangible,
more near term. I would ask you to focus on RA and ulcerative colitis beyond MS and Crohn's. And, we recently published the data on Crohn's disease, at the DDW. There is no question that Antegren will provide a very meaningful new addition to the treatment of patients with Crohn's. At least as efficacious, probably more, and substantially safer than current therapy. The MS data has not been released yet. It will be published in October, but through the actions by the FDA, we clearly suggest this drug will be more than exceptional.
Concerning the Alzheimer programs, we always have to remember that that is the core of our scientific effort. That is the cure of Alzheimer's disease is the reason for being for us as a company. Antegren was actually a spin-off of the Alzheimer programs. We have four very significant programs, and as Kelly said, we are
Comment
-
-
Mark,
Long Time.
How are you? Still in Boston? Married? Divorced? Kids? Did you ever get that operation you wanted?
I'm still in San Diego. I'm working at the Salk (www.salk.edu) doing database administration. We're actually looking for a senior network engineer (http://salk.edu/career/openings/staff.php Job #: 8911). Maybe you're qualified/interested.
Give me a call sometime: 858.967.2083
And remember, you can never hide from an italian.
Tony
Comment
-
Comment